Partnering for Bispecific Antibodies and ADCs: Biocytogen and Acepodia
Biocytogen (HKEX: 02315) and Acepodia (6976:TT) have announced a strategic partnership aimed at jointly evaluating a dual-payload bispecific antibody-drug conjugate (BsAD2C) program. This collaboration marks a significant step forward in their efforts to address complex tumors through innovative therapies, partnering to tackle the most difficult challenges in oncology, such as tumor heterogeneity and drug resistance.
Biocytogen and Acepodia are partnering to combine Biocytogen’s RenLite® platform with Acepodia’s Antibody-Dual-Drugs Conjugation (AD2C) technology to create a novel approach to cancer treatment. This unique collaboration utilizes dual-payloads that target multiple disease and therapeutic pathways, enhancing the precision and functionality of bispecific antibodies. By partnering in this effort, both companies aim to deliver innovative therapies that significantly improve the efficacy of cancer treatments.
As part of this partnership, Biocytogen will provide a bispecific antibody derived from its proprietary RenLite® platform. This platform is designed to generate fully human bispecific antibodies with unique binding properties, ensuring high precision in targeting cancer cells. Acepodia will integrate two distinct payloads into the bispecific antibody using its AD2C platform, further enhancing the antibody’s therapeutic potential.
The AD2C technology enables site-selective conjugation of multiple payloads to a single antibody using bio-orthogonal click chemistry. This partnering approach eliminates the need for antibody engineering, preserving the integrity and binding capacity of the antibody. The platform allows for precise control over the Drug-to-Antibody Ratio (DAR), ensuring optimal potency and safety for patients.
“We are thrilled to be partnering with Acepodia, who brings unmatched expertise in bio-orthogonal click chemistry,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “By combining our RenLite® bispecific antibodies with Acepodia’s site-selective dual-payload conjugates, we look forward to unlocking the therapeutic potential of highly potent bispecific antibody-drug conjugates (BsADCs). This partnership will further advance our commitment to improving patient outcomes.”
Acepodia’s CEO, Sonny Hsiao, Ph.D., expressed similar enthusiasm about partnering with Biocytogen: “Biocytogen’s superior bispecific antibodies and their highly collaborative approach make them the ideal partner for advancing our AD2C payload platform. By partnering, we can redefine the possibilities of ADC design, potentially delivering breakthrough therapies to patients who urgently need new treatment options.”
This strategic partnership highlights both companies’ commitment to addressing the significant unmet needs in antibody-drug conjugate (ADC) drug development for solid tumors. Partnering to overcome challenges like tumor heterogeneity and drug resistance, Biocytogen and Acepodia aim to deliver innovative therapies with the potential to transform cancer treatment and improve patient outcomes.
Biocytogen’s RenLite® platform is a leader in generating fully human bispecific antibodies, which have already shown promise in the development of novel therapeutic antibodies. With a strong pipeline and numerous partnerships with multinational pharmaceutical companies, Biocytogen is a pioneer in antibody-based therapies. The company’s commitment to advancing biotechnology is reflected in its broad pipeline of therapeutic antibodies, including those targeting solid tumors and hematologic malignancies. By partnering with Acepodia, Biocytogen is enhancing its ability to bring forward new therapeutic solutions in oncology.
Acepodia, known for its first-in-class immune cell engagers, has made substantial advancements in ADC technology. Through its partnership with Nobel Prize laureate Carolyn Bertozzi’s lab, Acepodia developed bio-orthogonal click chemistry technology that enables site-selective conjugation of multiple payloads to antibodies. This innovative platform enhances the safety, efficacy, and applicability of ADCs across a wide range of cancers, including both hematologic and solid tumor cancers.
Through this collaboration, Biocytogen and Acepodia are advancing ADC drug development by combining Biocytogen’s expertise in bispecific antibodies with Acepodia’s cutting-edge conjugation technology. By partnering, they are working to address the challenges of tumor complexity and drug resistance, providing patients with more effective and targeted treatments. This partnership marks a major step in the development of next-generation therapies for cancer and other diseases.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company specializing in the research and development of novel antibody-based drugs. Using its proprietary RenMice® platforms, Biocytogen generates fully human monoclonal and bispecific antibodies, antibody-drug conjugates (ADCs), and other advanced biologics. With a strong pipeline and numerous partnerships with multinational pharmaceutical companies, Biocytogen is at the forefront of developing cutting-edge therapies for cancer and other diseases.
About Acepodia
Acepodia is revolutionizing cancer and autoimmune disease treatments through first-in-class immune cell engagers that deliver enhanced potency and specificity via multiple conjugation platforms. With its bio-orthogonal click chemistry technology, Acepodia is making strides in the development of safer, more effective therapies for hematologic and solid tumors, as well as autoimmune diseases. By partnering with Biocytogen, Acepodia is further enhancing its ability to bring next-generation therapies to patients with unmet medical needs.
Please find the related post